| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/16/2009 | CA2388314C Imidazole derivatives as phosphodiesterase vii inhibitors |
| 06/16/2009 | CA2381097C Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
| 06/16/2009 | CA2361936C Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
| 06/16/2009 | CA2353063C Benzimidazole compounds that are vitronectin receptor antagonists |
| 06/16/2009 | CA2343732C Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto |
| 06/16/2009 | CA2334810C Method and device for delivery of therapeutic agents in conjunction with isotope seed placement |
| 06/16/2009 | CA2192786C Cyclopeptolide inhibitors of adhesion molecules |
| 06/16/2009 | CA2158322C Immunoconjugate comprising an anti-egf receptor antibody and interleukin-8 |
| 06/11/2009 | WO2009073885A1 Leukemic stem cell ablation |
| 06/11/2009 | WO2009073835A1 Oral compositions of abt-263 for treating cancer |
| 06/11/2009 | WO2009073575A2 Methods for treating induced cellular proliferative disorders |
| 06/11/2009 | WO2009073546A2 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7) |
| 06/11/2009 | WO2009073544A2 Methods for treating a disorder by regulating gprc6a |
| 06/11/2009 | WO2009073533A2 Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
| 06/11/2009 | WO2009073527A2 Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| 06/11/2009 | WO2009073524A2 Conjugates of anti-rg-1 antibodies |
| 06/11/2009 | WO2009073517A2 Intravesical compositions with valrubicin for the treatment of bladder cancer |
| 06/11/2009 | WO2009073445A2 Biocompatible biodegradable fumagillin analog conjugates |
| 06/11/2009 | WO2009073300A1 [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
| 06/11/2009 | WO2009073160A1 Anti-vegf antibodies |
| 06/11/2009 | WO2009073148A2 Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide) |
| 06/11/2009 | WO2009073147A2 Process for preparing bis(thiohydrazide amides) |
| 06/11/2009 | WO2009073139A2 Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit |
| 06/11/2009 | WO2009073133A1 Compositions of toll-like receptor agonists and papillomavirus antigens and uses thereof |
| 06/11/2009 | WO2009073115A1 Combination vegfr2 therapy with mtor inhibitors |
| 06/11/2009 | WO2009072831A2 Novel use of flj25416 gene |
| 06/11/2009 | WO2009072635A1 Method for amplifying hematopoietic stem cells using heterocyclic compound |
| 06/11/2009 | WO2009072628A1 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| 06/11/2009 | WO2009072626A1 Method for amplification of hematopoietic stem cell using heterocyclic compound |
| 06/11/2009 | WO2009072625A1 Amplification method for hematopoietic stem cells with heterocyclic compound |
| 06/11/2009 | WO2009072624A1 Method for amplification of hematopoietic stem cell using heterocyclic compound |
| 06/11/2009 | WO2009072610A1 Cancer vaccine composition |
| 06/11/2009 | WO2009072555A1 Cancer vaccine |
| 06/11/2009 | WO2009072267A1 Abcg2 inhibitor |
| 06/11/2009 | WO2009072120A1 Use of zinc in combination with chemotherapy for treating cancer |
| 06/11/2009 | WO2009072004A2 Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| 06/11/2009 | WO2009071892A2 Method for the detection of dead and dying cells |
| 06/11/2009 | WO2009071850A2 Nanoparticles of therapeutic agents having low water solubility |
| 06/11/2009 | WO2009071753A1 4-phenyl-1,3-thiazole and 4-phenyl-1,3-oxazole derivatives as cannabinoid receptor ligands |
| 06/11/2009 | WO2009071701A1 Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| 06/11/2009 | WO2009071620A1 Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management |
| 06/11/2009 | WO2009071535A1 Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| 06/11/2009 | WO2009071480A2 Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
| 06/11/2009 | WO2009071405A1 Megestrol acetate for reducing the mortality and/or improving quality of life in cancer patients |
| 06/11/2009 | WO2009071252A1 Nonsteroidal progesterone receptor modulators |
| 06/11/2009 | WO2009071161A1 Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders |
| 06/11/2009 | WO2009070844A1 Method of inhibition of leukemic stem cells |
| 06/11/2009 | WO2009055053A3 Diarylhydantoin compounds as androgen receptor modulators |
| 06/11/2009 | WO2009053804A3 Idarubicin for the treatment of lymphoma in a dog |
| 06/11/2009 | WO2009053467A3 The use of a non-glycanated polypeptide for treating a cancer |
| 06/11/2009 | WO2009052264A3 Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| 06/11/2009 | WO2009033818A3 Use of a peptide as a therapeutic agent |
| 06/11/2009 | WO2009033787A3 Use of a peptide as a therapeutic agent |
| 06/11/2009 | WO2009033786A3 Use of a peptide as a therapeutic agent |
| 06/11/2009 | WO2009033759A3 Use of a peptide as a therapeutic agent |
| 06/11/2009 | WO2009033740A3 Use of a peptide as a therapeutic agent |
| 06/11/2009 | WO2009033722A3 Use of a octreotide as a therapeutic agent |
| 06/11/2009 | WO2009033719A3 Use of a deslorelin and mastoparan as a therapeutic agent |
| 06/11/2009 | WO2009016516A3 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
| 06/11/2009 | WO2008157380A3 Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor |
| 06/11/2009 | WO2008098788A3 Receptor and antigen targeted prodrug |
| 06/11/2009 | WO2008060907A3 Pyrrolo-pyridine kinase inhibitors |
| 06/11/2009 | WO2003011214A3 Novel methods and formulations for administration of active agents |
| 06/11/2009 | WO2002099058A3 KCNMAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 06/11/2009 | WO2001070093A3 Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers |
| 06/11/2009 | US20090149652 Affinity for somatostatin receptors; used for the treatment of acromegalia, hypophyseal adenomas or endocrine gastroenteropancreatic tumors including carcinoid syndrome; 4-(urea or thiourea substituted)-1-alkylpiperidines |
| 06/11/2009 | US20090149635 Antibodies to human zcytor17 ligand |
| 06/11/2009 | US20090149516 desoxyepothilone A and B; Fludelone; anticarcinogenic agents; drug resistance; water solubility for formulability; industrial scale; cytotoxic or growth inhibitory effects on CAG myeloma cells lines; ability to polymerize tubulin; minimum toxicity; isomerization of the double bonds in the ring |
| 06/11/2009 | US20090149514 Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 06/11/2009 | US20090149513 Compositions of an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy |
| 06/11/2009 | US20090149511 Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
| 06/11/2009 | US20090149510 Compositions and methods for modulating a kinase cascade |
| 06/11/2009 | US20090149500 solid forms of lenalidomide, treating cancer, inflammatory disease, myelodysplastic syndrome, undesired angiogenesis |
| 06/11/2009 | US20090149499 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione) |
| 06/11/2009 | US20090149496 Inhibitors of the task-1 and task-3 ion channel |
| 06/11/2009 | US20090149494 THERAPEUTIC USE OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES |
| 06/11/2009 | US20090149493 Inhibitors of the interaction between mdm2 and p53 |
| 06/11/2009 | US20090149484 Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them |
| 06/11/2009 | US20090149476 3-[[6-[4-(1,2,3,4-tetrahydro-1,8-naphthyridin-7-yl)-1-piperidinyl]-2,5-dimethyl-4-pyrimidinyl]amino]-N-[(phenylmethoxy)carbonyl]alanine, used for the treatment of osteoporosis, restenosis, arteriosclerosis, nephropathy or retinopathy |
| 06/11/2009 | US20090149471 Monocyclic Heterocyclic Compounds |
| 06/11/2009 | US20090149470 aurora kinase inhibitors; 2-(thiazol-2-ylamino)pyridine compounds as antitumor agents; 6-((4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl)-N-thiazol-2-ylpyridin-2-amine for example |
| 06/11/2009 | US20090149469 Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors |
| 06/11/2009 | US20090149467 Tyrosine Kinase Inhibitors |
| 06/11/2009 | US20090149461 Method of treating cancer |
| 06/11/2009 | US20090149458 PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS |
| 06/11/2009 | US20090149457 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors |
| 06/11/2009 | US20090149456 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors |
| 06/11/2009 | US20090149454 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(5 -methyl-3-isoxazolyl)-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide; for prophylaxis and treatment of diseases, such as VEGF mediated diseases; cancer |
| 06/11/2009 | US20090149445 Tricyclic steroid hormone nuclear receptor modulators |
| 06/11/2009 | US20090149443 P38 inhibitors and methods of use thereof |
| 06/11/2009 | US20090149437 Thieno-pyridine derivatives as mek inhibitors |
| 06/11/2009 | US20090149430 Composition containing amidine derivatives or carboxamide derivatives and steroids, as a medicament |
| 06/11/2009 | US20090149427 Pharmaceutically acceptable salts and hydrates of risedronic acid |
| 06/11/2009 | US20090149424 Heparin conjugates and methods |
| 06/11/2009 | US20090149417 Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors |
| 06/11/2009 | US20090149415 Compounds for modulating the glycolysis enzyme complex and/or the transaminase complex |
| 06/11/2009 | US20090149413 RORS as Modifiers of the p21 Pathway and Methods of Use |
| 06/11/2009 | US20090149406 Plasmid PXL3179 or NV1FGF |
| 06/11/2009 | US20090149404 Oligonucleotide analogues and methods utilizing the same |
| 06/11/2009 | US20090149402 Pharmaceutical composition for treating cancer or diabetes |